Traumatic Brain Injury (TBI) is a serious and complex medical condition that affects millions of people worldwide each year. Early and accurate diagnosis is critical in determining the course of treatment and improving patient outcomes. However, current diagnostic methods such as CT and MRI scans can be expensive, time-consuming, and require a high level of expertise to interpret the results. Medicortex Finland Oy is on a mission to change that with their revolutionary, non-invasive, point-of-care diagnostic test for TBI.
Revolutionizing Brain Injury Diagnosis
Medicortex Finland Oy is a Finnish-based startup that is dedicated to developing a non-invasive, point-of-care diagnostic test for TBI and concussion. With a strong clinical evidence base and a unique biomarker that can be detected from urine and saliva, Medicortex is working towards the identification of brain injury biomarkers and their incorporation into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result.
The Problem with Current Diagnostic Methods
TBI is caused by an external force to the head that causes damage to the brain tissue. The severity of the injury can range from mild (concussion) to severe (coma). The symptoms of TBI can vary depending on the severity of the injury and can include headaches, dizziness, nausea, confusion, and memory loss. Accurate and early diagnosis of TBI is crucial for determining the course of treatment and improving patient outcomes.
Current diagnostic methods such as CT and MRI scans can be expensive, time-consuming, and require a high level of expertise to interpret the results. In addition, these methods are not always able to detect mild TBI, which is also known as concussions. This can lead to delayed or inaccurate diagnosis, which can have serious consequences for patients.
The Solution: A Non-Invasive, Point-of-Care Diagnostic Test
Medicortex Finland Oy is developing a non-invasive, point-of-care diagnostic test for TBI that can be used in hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), pharma and insurance companies. The test is based on a unique biomarker that can be detected from urine and saliva, making it easy to administer and interpret. With strong clinical evidence and a protected idea, Medicortex is willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution.
Accomplishments
Medicortex Finland Oy has made significant progress in developing its revolutionary diagnostic test for TBI. The company has reached Phase II Clinical studies of the biomarker, and has received grant funding from the US Department of Defense, the European Union, and the Finnish Government.
Conclusion
Medicortex Finland Oy is a Finnish-based startup that is dedicated to revolutionizing the way TBI is diagnosed. With their non-invasive, point-of-care diagnostic test, Medicortex is making it easier and faster to diagnose TBI and concussion, which can lead to improved patient outcomes. The company has made significant progress in its development, and with its strong clinical evidence base and unique biomarker, it is poised to make a significant impact in the medical industry.
Website: http://www.medicortex.fi/
Twitter: https://twitter.com/AdrianHarel?lang=fi
Facebook: https://www.facebook.com/medicortex/
LinkedIn: https://www.linkedin.com/company/16273371
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
